Genor Biopharma Holdings Limited (HK:6998) has released an update.
Genor Biopharma Holdings Limited reported a significant reduction in comprehensive loss to RMB132.3 million and a decrease in R&D expenses for the first half of 2024, compared to the same period in 2023. Revenue showed a positive turn with RMB14.5 million earned, primarily from research and manufacturing services. The company also announced promising clinical trial results for its breast cancer drug candidate, GB491, which met primary endpoints in a phase III study.
For further insights into HK:6998 stock, check out TipRanks’ Stock Analysis page.